Metabolic evaluation of children with global developmental delay

Global developmental delay (GDD) is a relatively common early-onset chronic neurological condition, which may have prenatal, perinatal, postnatal, or undetermined causes. Family history, physical and neurological examinations, and detailed history of environmental risk factors might suggest a specif...

Full description

Bibliographic Details
Main Authors: So-Hee Eun, Si Houn Hahn
Format: Article
Language:English
Published: Korean Pediatric Society 2015-04-01
Series:Korean Journal of Pediatrics
Subjects:
Online Access:http://kjp.or.kr/upload/pdf/kjped-58-117.pdf
id doaj-c97ce7f24c2e46b3b3b04d98d09d9a49
record_format Article
spelling doaj-c97ce7f24c2e46b3b3b04d98d09d9a492020-11-24T21:19:25ZengKorean Pediatric SocietyKorean Journal of Pediatrics1738-10612092-72582015-04-0158411712210.3345/kjp.2015.58.4.11720125550468Metabolic evaluation of children with global developmental delaySo-Hee Eun0Si Houn Hahn1Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.Division of Genetic Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.Global developmental delay (GDD) is a relatively common early-onset chronic neurological condition, which may have prenatal, perinatal, postnatal, or undetermined causes. Family history, physical and neurological examinations, and detailed history of environmental risk factors might suggest a specific disease. However, diagnostic laboratory tests, brain imaging, and other evidence-based evaluations are necessary in most cases to elucidate the causes. Diagnosis of GDD has recently improved because of remarkable advances in genetic technology, but this is an exhaustive and expensive evaluation that may not lead to therapeutic benefits in the majority of GDD patients. Inborn metabolic errors are one of the main targets for the treatment of GDD, although only a small proportion of GDD patients have this type of error. Nevertheless, diagnosis is often challenging because the phenotypes of many genetic or metabolic diseases often overlap, and their clinical spectra are much broader than currently known. Appropriate and cost-effective strategies including up-to-date information for the early identification of the "treatable" causes of GDD are needed for the development of well-timed therapeutic applications with the potential to improve neurodevelopmental outcomes.http://kjp.or.kr/upload/pdf/kjped-58-117.pdfMetabolismInborn errorsDevelopmental disabilities
collection DOAJ
language English
format Article
sources DOAJ
author So-Hee Eun
Si Houn Hahn
spellingShingle So-Hee Eun
Si Houn Hahn
Metabolic evaluation of children with global developmental delay
Korean Journal of Pediatrics
Metabolism
Inborn errors
Developmental disabilities
author_facet So-Hee Eun
Si Houn Hahn
author_sort So-Hee Eun
title Metabolic evaluation of children with global developmental delay
title_short Metabolic evaluation of children with global developmental delay
title_full Metabolic evaluation of children with global developmental delay
title_fullStr Metabolic evaluation of children with global developmental delay
title_full_unstemmed Metabolic evaluation of children with global developmental delay
title_sort metabolic evaluation of children with global developmental delay
publisher Korean Pediatric Society
series Korean Journal of Pediatrics
issn 1738-1061
2092-7258
publishDate 2015-04-01
description Global developmental delay (GDD) is a relatively common early-onset chronic neurological condition, which may have prenatal, perinatal, postnatal, or undetermined causes. Family history, physical and neurological examinations, and detailed history of environmental risk factors might suggest a specific disease. However, diagnostic laboratory tests, brain imaging, and other evidence-based evaluations are necessary in most cases to elucidate the causes. Diagnosis of GDD has recently improved because of remarkable advances in genetic technology, but this is an exhaustive and expensive evaluation that may not lead to therapeutic benefits in the majority of GDD patients. Inborn metabolic errors are one of the main targets for the treatment of GDD, although only a small proportion of GDD patients have this type of error. Nevertheless, diagnosis is often challenging because the phenotypes of many genetic or metabolic diseases often overlap, and their clinical spectra are much broader than currently known. Appropriate and cost-effective strategies including up-to-date information for the early identification of the "treatable" causes of GDD are needed for the development of well-timed therapeutic applications with the potential to improve neurodevelopmental outcomes.
topic Metabolism
Inborn errors
Developmental disabilities
url http://kjp.or.kr/upload/pdf/kjped-58-117.pdf
work_keys_str_mv AT soheeeun metabolicevaluationofchildrenwithglobaldevelopmentaldelay
AT sihounhahn metabolicevaluationofchildrenwithglobaldevelopmentaldelay
_version_ 1726005417860923392